Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
Open accessThe DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable interstitial lung disorder with an obscure origin and inadequately comprehended pathological mechanisms. Despite the intricate and uncharted causes and pathways of IPF, the scholarly consensus upholds that the transformation of fibroblasts into myofibroblasts—instigated by injury to the alveolar epithelial cells—and the disproportionate accumulation of extracellular matrix (ECM) components, such as collagen, are integral to IPF’s progression. The introduction of two novel anti-fibrotic medications, pirfenidone and nintedanib, have exhibited efficacy in decelerating the ongoing degradation of lung function, lessening hospitalization risk, and postponing exacerbations among IPF patients. Nonetheless, these pharmacological interventions do not present a definitive solution to IPF, positioning lung transplantation as the solitary potential curative measure in contemporary medical practice. A host of innovative therapeutic strategies are presently under rigorous scrutiny. This comprehensive review encapsulates the recent advancements in IPF research, spanning from diagnosis and etiology to pathological mechanisms, and introduces a discussion on nascent therapeutic methodologies currently in the pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Preclinical studies demonstrated suppression of SMURF2 leads to decreased bleomycin induced pulmonary fibrosis [187–189].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [187]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Liu, Y., Guan, Y., Shen, J. F., Jia, Y.-L., Zhou, J., Sun, Y., Jiang, J., Shen, H., Shu, Q., Xie, Q.-M., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01426-9 · Cited by 24 · cited 1×
“Fostering epithelial-mesenchymal transition (Liu et al., 2020); 2.”
RetractedQian, W., Cai, X., Qian, Q., & Zhang, X. (2021) · BioMed Research International · doi:10.1155/2021/5545312 · Cited by 9 · cited 1×
“, 2021), compounded by progressive scarring of lung tissue and interstitial lung disease (Qian et al., 2021).”
BackgroundRetractedEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Nintedanib significantly mitigated the risk of disease progression and also demonstrated a mortality-reducing benefit (Richeldi et al., 2014).”
BackgroundDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103 · cited 1×
“IPF prevalence and incidence continue to rise in individuals over 65 years and remain exceedingly rare in those under 50 years old (Raghu et al., 2018), reinforcing the classification of IPF as an agingrelated disease.”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 1×
“, 2018), as has been demonstrated in numerous randomized, placebo-controlled phase III trials (King et al., 2014; Noble et al., 2016).”
BackgroundCellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · cited 1×
“Multiple murine models of pulmonary fibrosis display evidence of various cellular senescence markers, including heightened aging-associated β-galactosidase in lysosomes, an increased BCL-2/Bax ratio of apoptosis-involved proteins in mitochondria, and amplified DNA damage in the nucleus (Schafer et al., 2017; Blokland…”
BackgroundBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Nintedanib effectively impairs the activity of platelet-derived growth factor receptor kinase, fibroblast growth factor receptor kinase, and vascular endothelial growth factor receptor kinase (Hilberg et al., 2008).”
BackgroundMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“It suppresses the release of pro-inflammatory and pro-fibrotic mediators, inhibits fibroblast migration and differentiation, and contributes to the blockade of extracellular matrix deposition (Wollin et al., 2015).”
BackgroundUnderstanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686 · cited 1×
“2 Metformin Metformin, a time-honored hypoglycemic agent clinically employed in the treatment of type 2 diabetes mellitus, is increasingly recognized for its antifibrotic properties, as corroborated by numerous preclinical investigations (Choi et al., 2016; Rangarajan et al., 2018; Foretz et al., 2019).”
BackgroundIdiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573 · cited 1×
“It has been observed that nearly all sporadic IPF patients present shortened telomeres in alveolar epithelial cells (Sgalla et al., 2018).”
BackgroundThe role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis
Molyneaux, P. L., Cox, M. J., Willis-Owen, S. A. G., Mallia, P., Russell, K. E., Russell, A.-M., Murphy, E., Johnston, S. L., Schwartz, D. A., Wells, A. U., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0541oc · Cited by 567 · cited 2×
“Furthermore, it has been reported that the mortality risk in IPF escalates with the increasing bacterial burden in the lung (Molyneaux et al., 2014).”
BackgroundMetformin reverses established lung fibrosis in a bleomycin model
Rangarajan, S., Bone, N. B., Zmijewska, A. A., Jiang, S., Park, D. W., Bernard, K., Locy, M. L., Ravi, S., Deshane, J., Mannon, R. B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0087-6 · Cited by 560
Developmental pathways in the pathogenesis of lung fibrosis
Chanda, D., Otoupalova, E., Smith, S. R., Volckaert, T., De Langhe, S. P., & Thannickal, V. J. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.08.004 · Cited by 514 · cited 1×
“TGF-β is considered a central component among the diverse factors contributing to pulmonary fibrosis development (Chanda et al., 2019).”
BackgroundNoble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468 · cited 1×
“, 2018), as has been demonstrated in numerous randomized, placebo-controlled phase III trials (King et al., 2014; Noble et al., 2016).”
BackgroundComorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463 · cited 1×
“Systemic steroids, due to a dearth of effective alternatives, served as the standard treatment for IPF (Raghu et al., 2015).”
BackgroundTargeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 450 · cited 1×
“Mutations in the mucin 5B gene have emerged as one of the most influential risk factors for IPF (Wang et al., 2022).”
BackgroundLee, J. S., Ryu, J. H., Elicker, B. M., Lydell, C. P., Jones, K. D., Wolters, P. J., King, T. E., & Collard, H. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0138oc · Cited by 437 · cited 1×
“Several studies generally vouch for the beneficial effects of PPI therapy in managing IPF, where PPIs could decelerate lung function deterioration and enhance patient survival (Lee et al., 2011; Lee et al., 2013).”
BackgroundInhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Dinh, P.-U. C., Paudel, D., Brochu, H., Popowski, K. D., Gracieux, M. C., Cores, J., Huang, K., Hensley, M. T., Harrell, E., Vandergriff, A. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14344-7 · Cited by 435 · cited 1×
“substantially less lung inflammation and fibrosis (Dinh et al., 2020).”
Lee, J. S., Collard, H. R., Anstrom, K. J., Martinez, F. J., Noth, I., Roberts, R. S., Yow, E., & Raghu, G. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70105-x · Cited by 413 · cited 1×
“Several studies generally vouch for the beneficial effects of PPI therapy in managing IPF, where PPIs could decelerate lung function deterioration and enhance patient survival (Lee et al., 2011; Lee et al., 2013).”
BackgroundAghapour, M., Raee, P., Moghaddam, S. J., Hiemstra, P. S., & Heijink, I. H. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0200tr · Cited by 393 · cited 1×
“Recognized as a principal risk factor for chronic respiratory diseases such as COPD (Aghapour et al., 2018), smoking also has a significant role in precipitating pulmonary fibrosis.”
BackgroundIdiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382 · cited 1×
“An increasing number of clinical trials have shown that antiinflammatory therapy and immunosuppressive agents are not effective in conventional treatment of IPF (Ryu et al., 2014; Barratt et al., 2018), leading to the discontinuation of their recommendation for the routine treatment of IPF.”
BackgroundLung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis
O’Dwyer, D. N., Ashley, S. L., Gurczynski, S. J., Xia, M., Wilke, C., Falkowski, N. R., Norman, K. C., Arnold, K. B., Huffnagle, G. B., Salisbury, M. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1650oc · Cited by 366 · cited 1×
“Research conducted by David and colleagues unveiled a significant correlation between the lung microbiota burden and IPF progression (O’Dwyer et al., 2019).”
BackgroundIdiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360 · cited 2×
“Aging can impede stem cell turnover functionality, obstructing the repair and regeneration of alveolar epithelial cells in damaged lungs (Mei et al., 2021).”
BackgroundWhat's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis
Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03693-7 · Cited by 351 · cited 3×
“Frequently, particulate matter, fibers, and dust constitute the primary environmental contributors to IPF onset (Phan et al., 2021).”
BackgroundInfluentialNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335 · cited 1×
“It can enhance the prognosis of IPF, reduce mortality, and prolong progression-free survival (Nathan et al., 2017; Vancheri et al., 2018), as has been demonstrated in numerous randomized, placebo-controlled phase III trials (King et al.”
BackgroundConnective tissue growth factor (CTGF) from basics to clinics
Ramazani, Y., Knops, N., Elmonem, M. A., Nguyen, T. Q., Arcolino, F. O., van den Heuvel, L., Levtchenko, E., Kuypers, D., & Goldschmeding, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.007 · Cited by 329 · cited 1×
“Frequently expressed in mesenchymal cell lines, CTGF often directs tissue regeneration and pathological fibrosis formation via ECM deposition, fibroblast proliferation, and matrix generation (Ramazani et al., 2018).”
BackgroundStuart, B. D., Lee, J. S., Kozlitina, J., Noth, I., Devine, M. S., Glazer, C. S., Torres, F., Kaza, V., Girod, C. E., Jones, K. D., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70124-9 · Cited by 310 · cited 1×
“Research indicates that cellular senescence induced by telomere degradation primarily afflicts alveolar epithelial type II cells, which is intricately linked to IPF pathogenesis (Stuart et al., 2014; Selman et al., 2019).”
BackgroundIdiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308 · cited 1×
“Genetic constituents serve as fundamental drivers in the initiation and evolution of IPF (Ballester et al., 2019).”
BackgroundNintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
Lung transplantation for idiopathic pulmonary fibrosis
George, P. M., Patterson, C. M., Reed, A. K., & Thillai, M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30502-2 · Cited by 297 · cited 1×
“Candidates typically considered for lung transplantation are those with limited treatment alternatives and face a death risk exceeding 50% within 2 years without the transplantation (George et al., 2019).”
BackgroundImmune dysregulation as a driver of idiopathic pulmonary fibrosis
Shenderov, K., Collins, S. L., Powell, J. D., & Horton, M. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143226 · Cited by 295 · cited 1×
“Therapeutic interventions are currently limited, with only two FDA-endorsed pharmaceuticals in the United States, namely, pirfenidone and nintedanib (Shenderov et al., 2021).”
BackgroundRicheldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30262-0 · Cited by 293 · cited 1×
“Some clinical trials have showcased promising results with pamrevlumab significantly reducing FVC deterioration and slowing disease progression, exhibiting comparable efficacy to pirfenidone and nintedanib (Sgalla et al., 2020a; Richeldi et al., 2020).”
BackgroundMetformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis
Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., Weiss, A., Wilhelm, J., Zhang, J.-S., Kwapiszewska, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10839-0 · Cited by 293 · cited 1×
“Metformin was identified to exert pronounced antifibrotic effects by modulating metabolic pathways, impeding transforming growth factor-beta, inhibiting collagen formation, and inducing adipogenic differentiation of lung fibroblasts in IPF patients (Kheirollahi et al., 2019).”
BackgroundPhysiology of the lung in idiopathic pulmonary fibrosis
Plantier, L., Cazes, A., Dinh-Xuan, A.-T., Bancal, C., Marchand-Adam, S., & Crestani, B. (2018) · European Respiratory Review · doi:10.1183/16000617.0062-2017 · Cited by 259 · cited 1×
“Furthermore, both acute and chronic fibrotic lung diseases transpire in patients with mutations in pulmonary surfactant apolipoprotein and lipid transporter (Plantier et al., 2018), insinuating a significant role of surfactant composition or metabolic alterations in IPF.”
BackgroundHepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252 · cited 1×
“Composed of 70 amino acids, IGF-1 chiefly mediates a range of biological functions, including cell division, differentiation, apoptosis, and metabolism (Jensen-Cody and Potthoff, 2021; Jiang et al., 2023).”
BackgroundYang, D., Chen, X., Wang, J., Lou, Q., Lou, Y., Li, L., Wang, H., Chen, J., Wu, M., Song, X., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.001 · Cited by 250 · cited 1×
“Additionally, IL-17B and TNF-a secreted by these extracellular vesicles interact to construct an inflammatory network system conducive to pulmonary fibrosis (Yang et al., 2019).”
BackgroundGlassberg, M. K., Minkiewicz, J., Toonkel, R. L., Simonet, E. S., Rubio, G. A., DiFede, D., Shafazand, S., Khan, A., Pujol, M. V., LaRussa, V. F., et al. (2017) · Chest · doi:10.1016/j.chest.2016.10.061 · Cited by 249 · cited 1×
“Nomajor adverse events were reported, thereby alleviating the majority of concerns (Glassberg et al., 2017; Zhang et al., 2017; Campo et al., 2021).”
BackgroundTrial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236 · cited 1×
“PDE4 inhibition is renowned for its anti-inflammatory and antifibrotic properties (Richeldi et al., 2022).”
BackgroundMetformin attenuates lung fibrosis development via NOX4 suppression
Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0420-x · Cited by 228 · cited 1×
“This activation fast-tracked the removal of established fibrosis by promoting myofibroblast inactivation and apoptosis (Choi et al., 2016; Sato et al., 2016).”
BackgroundImpact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220 · cited 1×
“, 2020), acting to inhibit fibrotic processes via the suppression of the cytokine TGFβ (Petnak et al., 2021).”
BackgroundTGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)
Ye, Z., & Hu, Y. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4965 · Cited by 219
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 212 · cited 1×
“Nintedanib is a small molecule tyrosine kinase inhibitor that targets receptors, leading to a broad inhibition of downstream signaling pathways in fibroblasts and myofibroblasts (Wind et al., 2019).”
BackgroundLung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis
Pardo, A., & Selman, M. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201605-341aw · Cited by 204 · cited 1×
“Repeated microdamage to senescent epithelial cells in genetically susceptible individuals can trigger abnormal fibroblast activation, culminating in ECM accumulation and fibrosis (Pardo and Selman, 2016).”
BackgroundOlson, A. L., Gifford, A. H., Inase, N., Fernández Pérez, E. R., & Suda, T. (2018) · European Respiratory Review · doi:10.1183/16000617.0077-2018 · Cited by 200 · cited 1×
“The principal objective of IPF management is to alleviate symptoms, enhance patient health and quality of life, and maintain lung function as a means to extend survival (Olson et al., 2018).”
BackgroundTime for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30007-9 · Cited by 196 · cited 1×
“A growing body of evidence indicates that susceptibility to IPF is linked to a complex interplay of genetic variations and alterations in transcriptional activity (Wolters et al., 2018).”
BackgroundIdiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, C. S., & Nathan, S. D. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30222-3 · Cited by 186 · cited 1×
“Chronic microaspiration stemming from GERD is deemed a likely precursor to IPF (King and Nathan, 2017).”
Background‘WNT-er is coming’: WNT signalling in chronic lung diseases
Baarsma, H. A., & Königshoff, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209753 · Cited by 185 · cited 1×
“These lung fibroblast-derived exosomes exert an autocrine effect, stimulating in vitro fibroblast proliferation (Baarsma and Konigshoff, 2017).”
BackgroundIncreased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis
Martin-Medina, A., Lehmann, M., Burgy, O., Hermann, S., Baarsma, H. A., Wagner, D. E., De Santis, M. M., Ciolek, F., Hofer, T. P., Frankenberger, M., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1580oc · Cited by 183
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review
Kinoshita, T., & Goto, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061461 · Cited by 176 · cited 1×
“Moreover, TGF-β distinguishes itself as the most efficacious extracellular matrix production stimulant and is considered the strongest chemoattractant for immune cells, including monocytes and macrophages (Kinoshita and Goto, 2019).”
BackgroundRaghu, G., Scholand, M. B., de Andrade, J., Lancaster, L., Mageto, Y., Goldin, J., Brown, K. K., Flaherty, K. R., Wencel, M., Wanger, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01030-2015 · Cited by 175 · cited 2×
“Data derived from a phase 2 study underscored a favorable safety and tolerability profile for pamrevlumab among the IPF patients participating in the study (Raghu et al., 2016).”
BackgroundCurrent Perspectives on the Treatment of Idiopathic Pulmonary Fibrosis
Walter, N., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200602-016tk · Cited by 174 · cited 1×
“Combinatorial immunosuppressants, including prednisone, azathioprine, cyclophosphamide, and acetylcysteine, were similarly efficacious (Walter et al., 2006).”
BackgroundOPTN/SRTR 2019 annual data report: lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Miller, E., Goff, R., Foutz, J., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16495 · Cited by 161
Zhang, Y., Huang, W., Zheng, Z., Wang, W., Yuan, Y., Hong, Q., Lin, J., Li, X., & Meng, Y. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.013 · Cited by 160
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0037 · Cited by 158 · cited 1×
“In terms of efficacy, patients receiving the treatment displayed significant improvement in FVC compared to the placebo group (Ntolios et al., 2018; Fishman et al., 2019; Averyanov et al., 2020), with these results being considerably encouraging.”
ResultRana, T., Jiang, C., Liu, G., Miyata, T., Antony, V., Thannickal, V. J., & Liu, R.-M. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0071oc · Cited by 157
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis
Bickelhaupt, S., Erbel, C., Timke, C., Wirkner, U., Dadrich, M., Flechsig, P., Tietz, A., Pföhler, J., Gross, W., Peschke, P., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw339 · Cited by 151 · cited 2×
“Indeed, the utilization of anti-CTGF antibodies in fibrotic animal models attenuates ECM component expression, enhances survival post-radiation-induced lung injury, and conserves the morphology of alveolar epithelial cells (Bickelhaupt et al., 2017).”
BackgroundPharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148 · cited 1×
“Pirfenidone exhibits anti-inflammatory, anti-oxidative, and anti-fibrotic properties, thereby reducing collagen synthesis and deposition in the lungs (Saito et al., 2019).”
BackgroundGhebremariam, Y. T., Cooke, J. P., Gerhart, W., Griego, C., Brower, J., Doyle‐Eisele, M., Moeller, B. C., Zhou, Q., Ho, L. A., de Andrade, J. A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0614-x · Cited by 147 · cited 2×
“Preclinical in vivo studies demonstrated that oral esomeprazole mitigated inflammation and fibrosis in rodent models of bleomycin-induced lung injury, with approximately 50% reduction in each parameter (Ghebremariam et al., 2015).”
BackgroundMatrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis
Mahalanobish, S., Saha, S., Dutta, S., & Sil, P. C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104591 · Cited by 147 · cited 2×
“Research has demonstrated that mice with MMP-3 deletion or MMP-7 knockout are safeguarded from bleomycin-induced fibrosis (Mahalanobish et al., 2020).”
BackgroundIdiopathic Pulmonary Fibrosis: Evolving Concepts
Ryu, J. H., Moua, T., Daniels, C. E., Hartman, T. E., Yi, E. S., Utz, J. P., & LIMPER, A. H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.03.016 · Cited by 143 · cited 1×
“An increasing number of clinical trials have shown that antiinflammatory therapy and immunosuppressive agents are not effective in conventional treatment of IPF (Ryu et al., 2014; Barratt et al., 2018), leading to the discontinuation of their recommendation for the routine treatment of IPF.”
BackgroundGhavami, S., Yeganeh, B., Zeki, A. A., Shojaei, S., Kenyon, N. J., Ott, S., Samali, A., Patterson, J., Alizadeh, J., Moghadam, A. R., et al. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00372.2017 · Cited by 138
Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838449 · Cited by 137 · cited 1×
“Several experiments have established the inhibition of pulmonary fibrosis by PDE4 inhibitors (Kim et al., 2016; Herrmann et al., 2022).”
BackgroundTobacco Smoking and Risk for Pulmonary Fibrosis
Bellou, V., Belbasis, L., & Εvangelou, Ε. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.04.035 · Cited by 136 · cited 1×
“correlation exists between smoking and IPF, which amplifies with the escalation in dosage, especially evident in habitual smokers or those who have smoked over extended periods (Bellou et al., 2021).”
BackgroundAntifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 134 · cited 1×
“Phase 3 clinical trials demonstrated that, compared to a placebo, nintedanib significantly attenuates the decline rate of forceful lung volume following mild to moderate lung function impairment in IPF patients (Collins and Raghu, 2019).”
BackgroundEffects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 133
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133 · cited 1×
“IPF patients exhibit elevated MMP levels in alveolar lavage fluid and blood (Inoue et al., 2020; Espindola et al., 2021).”
BackgroundBiomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132 · cited 1×
“Telomeres, non-coding, repetitive nucleotide sequences situated at chromosome extremities, shield chromosomes from progressive attrition during typical cellular replication (Drakopanagiotakis et al., 2018).”
BackgroundRegulation of cellular senescence by extracellular matrix during chronic fibrotic diseases
Blokland, K. E. C., Pouwels, S. D., Schuliga, M., Knight, D. A., & Burgess, J. K. (2020) · Clinical Science · doi:10.1042/cs20190893 · Cited by 128 · cited 1×
“Multiple murine models of pulmonary fibrosis display evidence of various cellular senescence markers, including heightened aging-associated β-galactosidase in lysosomes, an increased BCL-2/Bax ratio of apoptosis-involved proteins in mitochondria, and amplified DNA damage in the nucleus (Schafer et al., 2017; Blokland…”
BackgroundMeta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis
Méthot, D. B., Leblanc, É., & Lacasse, Y. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.07.038 · Cited by 125
Naccache, J.-M., Jouneau, S., Didier, M., Borie, R., Cachanado, M., Bourdin, A., Reynaud-Gaubert, M., Bonniaud, P., Israël-Biet, D., Prévot, G., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00354-4 · Cited by 121
Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β
Nolte, M., & Margadant, C. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.10.002 · Cited by 120 · cited 1×
“As a multifunctional cytokine, TGF-β fosters pulmonary fibrosis through a range of mechanisms (Nolte and Margadant, 2020).”
BackgroundSenotherapeutics: targeting senescence in idiopathic pulmonary fibrosis
Merkt, W., Bueno, M., Mora, A. L., & Lagares, D. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.008 · Cited by 119 · cited 1×
“Cellular senescence can disrupt various cellular biological activities in the body, manifesting as telomere attrition, DNA damage, and mitochondrial dysfunction (Merkt et al., 2020).”
BackgroundKumar, A., Cherian, S. V., Vassallo, R., Yi, E. S., & Ryu, J. H. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.023 · Cited by 118 · cited 1×
“Cigarette smoke can inflict damage on all lung cell types, particularly alveolar epithelial cells, giving rise to diffuse infiltration and parenchymal fibrosis (Kumar et al., 2018).”
BackgroundConnective-Tissue Growth Factor Contributes to TGF-β1–induced Lung Fibrosis
Yanagihara, T., Tsubouchi, K., Gholiof, M., Chong, S. G., Lipson, K. E., Zhou, Q., Scallan, C. J., Upagupta, C., Tikkanen, J., Keshavjee, S., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0504oc · Cited by 118 · cited 1×
“CTGF is a primary mediator of TGF-β-induced pulmonary fibrosis (Yanagihara et al., 2022).”
BackgroundUse of animal models in IPF research
Carrington, R., Jordan, S., Pitchford, S. C., & Page, C. P. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.07.002 · Cited by 115 · cited 1×
“Several animal model studies in recent years have corroborated the antifibrotic characteristics of pirfenidone (Carrington et al., 2018).”
ResultPark, Y., Ahn, C., & Kim, T.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-81591-z · Cited by 107 · cited 1×
“Studies suggest that air pollution may incite epigenetic modifications in the lung, enhancing pathogenicity in synergy with other antigens (Park et al., 2021), and potentially initiating or fostering disruptions in alveolar damage and repair mechanisms.”
BackgroundIdiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs
Ghebre, Y. T., & Raghu, G. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2316pp · Cited by 107 · cited 1×
“PPIs are further recognized to exhibit antifibrotic effects by upregulating the cytoprotective enzyme heme oxygenase 1 (Ghebre and Raghu, 2016).”
BackgroundShimbori, C., Upagupta, C., Bellaye, P., Ayaub, E. A., Sato, S., Yanagihara, T., Zhou, Q., Ognjanovic, A., Ask, K., Gauldie, J., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-211516 · Cited by 106 · cited 1×
“Released in response to epithelial cell injury, TGF-β acts as a key upstream pro-fibrotic growth factor propelling the disease’s pathophysiology (Shimbori et al., 2019; He et al., 2021b).”
BackgroundParimon, T., Yao, C., Habiel, D. M., Ge, L., Bora, S. A., Brauer, R., Evans, C. M., Xie, T., Alonso-Valenteen, F., Medina-Kauwe, L. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129359 · Cited by 104 · cited 1×
“A multitude of studies underscore the significance of exosomes in IPF pathogenesis, particularly regarding epithelial phenotypes and fibroproliferative responses (d’Alessandro et al., 2021a; MartinMedina et al., 2018; Parimon et al., 2019).”
Backgroundon behalf of the IPF-PRO Registry investigators, Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1103-4 · Cited by 104 · cited 1×
“MMPs are proactive contributors to pulmonary fibrosis (Todd et al., 2020).”
BackgroundDong, L.-H., Jiang, Y.-Y., Liu, Y.-J., Cui, S., Xia, C.-C., Qu, C., Jiang, X., Qu, Y.-Q., Chang, P.-Y., & Liu, F. (2015) · Scientific Reports · doi:10.1038/srep08713 · Cited by 103
Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice
Bormann, T., Maus, R., Stolper, J., Tarrés, M. T., Brandenberger, C., Wedekind, D., Jonigk, D. D., Welte, T., Gauldie, J., Kolb, M. R. J., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02105-7 · Cited by 101
Vascular permeability in the fibrotic lung
Probst, C. K., Montesi, S. B., Medoff, B. D., Shea, B. S., & Knipe, R. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.00100-2019 · Cited by 94 · cited 1×
“MMP-7 expression is enhanced in both human IPF and mouse fibrosis models (Mahalanobish et al., 2020; Probst et al., 2020).”
BackgroundLung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 91 · cited 1×
“versus-host disease, and the risk of infection (Kapnadak and Raghu, 2021).”
BackgroundPirfenidone for idiopathic pulmonary fibrosis and beyond
Aimo, A., Spitaleri, G., Nieri, D., Tavanti, L. M., Meschi, C., Panichella, G., Lupón, J., Pistelli, F., Carrozzi, L., Bayes-Genis, A., et al. (2022) · Cardiac Failure Review · doi:10.15420/cfr.2021.30 · Cited by 88 · cited 4×
“By inhibiting the cytokine TGF-β, it curtails the proliferation, differentiation, and collagen secretion of human lung fibroblasts, decelerates the fibrotic process, and attenuates the decline rate of forced vital capacity (FVC) (Aimo et al., 2022).”
BackgroundInfluentialSeibold, J. R., Maher, T. M., Highland, K. B., Assassi, S., Azuma, A., Hummers, L. K., Costabel, U., von Wangenheim, U., KOHLBRENNER, V. M., Gahlemann, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217331 · Cited by 87
Aging Reprograms the Hematopoietic-Vascular Niche to Impede Regeneration and Promote Fibrosis
Chen, Y., Pu, Q., Ma, Y., Zhang, H., Ye, T., Zhao, C., Huang, X., Ren, Y., Qiao, L., Liu, H.-M., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.019 · Cited by 86 · cited 1×
“Aging has been implicated in promoting fibrosis by thwarting blood vessel regeneration (Chen et al., 2021).”
BackgroundAbreu, S. C., Lopes-Pacheco, M., Weiss, D. J., & Rocco, P. R. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.600711 · Cited by 86 · cited 1×
“Bronchial epithelial cells primarily generate exosomes in the lungs, which activate fibroblasts, stimulate their differentiation into myofibroblasts, and catalyze excessive extracellular matrix component deposition (Abreu et al., 2021).”
BackgroundHenry, E., Cores, J., Hensley, M. T., Anthony, S., Vandergriff, A., de Andrade, J. B. M., Allen, T., Caranasos, T. G., Lobo, L. J., & Cheng, K. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0062 · Cited by 77
Le, Y., Cao, W., Zhou, L., Fan, X., Liu, Q., Liu, F., Gai, X., Chang, C. H., Xiong, J., Rao, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01902 · Cited by 77 · cited 1×
“Inducing m acrophage polarization (Le et al., 2020); 3.”
Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions
Stainer, A., Faverio, P., Busnelli, S., Catalano, M., Della Zoppa, M., Marruchella, A., Pesci, A., & Luppi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126255 · Cited by 76 · cited 1×
“A pivotal study unveiled a prevalent single nucleotide polymorphism in the promoter domain of the MUC5B gene on chromosome 11 (Stainer et al., 2021), predominantly associated with pulmonary fibrosis (Biondini et al.”
BackgroundThe impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis
Menou, A., Duitman, J., & Crestani, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.001 · Cited by 75
Idiopathic pulmonary fibrosis and GERD: links and risks
Ghisa, M., Marinelli, C., Savarino, V., & Savarino, E. V. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s184291 · Cited by 75 · cited 1×
“For individuals predisposed to IPF, chronic microaspiration induced by gastric reflux can inflict enduring, recurrent damage to lung tissue, increasing lung epithelial cell permeability, continually stimulating pulmonary fibrosis proliferation, and eventually contributing to the manifestation of pulmonary fibrosis (Gh…”
BackgroundReynolds, C., Fabiola Del Greco, M., Allen, R. J., Flores, C., Jenkins, G. R., Maher, T. M., Molyneaux, P. L., Noth, I., Oldham, J. M., Wain, L. V., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01585-2022 · Cited by 75 · cited 1×
“Evidence supporting this hypothesis emerges from descriptive studies conducted in both experimental animal models and humans (Chen et al., 2019; Reynolds et al., 2023).”
Spagnolo, P., Molyneaux, P. L., Bernardinello, N., Cocconcelli, E., Biondini, D., Fracasso, F., Tinè, M., Saetta, M. P., Maher, T. M., & Balestro, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225618 · Cited by 74 · cited 1×
“Recent investigations underscore the crucial role of microbiota in inciting and exacerbating pulmonary fibrosis in animal models, thereby elucidating the association between microbiota and pulmonary fibrosis (Spagnolo et al., 2019).”
BackgroundPirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence
Aimo, A., Cerbai, E., Bartolucci, G., Adamo, L., Barison, A., Lo Surdo, G., Biagini, S., Passino, C., & Emdin, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104694 · Cited by 74 · cited 1×
“Pirfenidone, a small molecule pyridine, possesses anti-fibrotic, antiinflammatory, and antioxidant properties (Aimo et al., 2020), acting to inhibit fibrotic processes via the suppression of the cytokine TGFβ (Petnak et al.”
BackgroundIPF pathogenesis is dependent upon TGFβ induction of IGF‐1
Hernandez, D. M., Kang, J. H., Choudhury, M., Andrianifahanana, M., Yin, X., LIMPER, A. H., & Leof, E. B. (2020) · The FASEB Journal · doi:10.1096/fj.201901719rr · Cited by 74 · cited 1×
“Further research has shown that TGF-β is crucial for IGF-1 induction in myofibroblasts, and increased levels of IGF-1 in IPF tissues are associated with diminished lung function during disease progression (Hernandez et al., 2020).”
BackgroundNathan, S. D., Behr, J., Cottin, V., Lancaster, L., Smith, P., Deng, C., Pearce, N., Bell, H., Peterson, L., & Flaherty, K. R. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001310 · Cited by 73 · cited 1×
“Treprostinil is a stable prostacyclin analog, a PGI2 receptor agonist, promoting vasodilation and inhibiting platelet aggregation (Nathan et al., 2022).”
BackgroundIGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That of Other Pro-fibrotic Mediators
Nguyen, X.-X., Muhammad, L., Nietert, P. J., & Feghali-Bostwick, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00601 · Cited by 72
Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors
Sack, C., & Raghu, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.01699-2018 · Cited by 72 · cited 2×
“These contaminants are identified as precipitators of oxidative stress, epithelial damage, and airway inflammation (Sack and Raghu, 2019).”
BackgroundSurolia, R., Li, F. J., Wang, Z., Li, H., Liu, G., Zhou, Y., Luckhardt, T., Bae, S., Liu, R.-M., Rangarajan, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91377 · Cited by 68 · cited 1×
“Lung spheroid cells (LSCs), forming a distinct spherical structure in culture, comprise stem and support cells native to the lungs that can be reliably cultured from biopsied lung tissue (Surolia et al., 2017).”
BackgroundConnective tissue growth factor (CTGF) in age-related vascular pathologies
Ungvari, Z. I., Valcarcel‐Ares, M. N., Tarantini, S., Yabluchanskiy, A., Fülöp, G., Kiss, T., & Csiszár, A. (2017) · GeroScience · doi:10.1007/s11357-017-9995-5 · Cited by 65 · cited 1×
“As a cysteine-rich stromal cell protein, it exerts influence over numerous biological processes, including cell proliferation, differentiation, adhesion, angiogenesis, and multiple pathological processes such as tumorigenesis and tissue fibrosis (Ungvari et al., 2017).”
BackgroundRenaud, L., da Silveira, W. A., Takamura, N., Hardiman, G., & Feghali‐Bostwick, C. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00383 · Cited by 64 · cited 1×
“IGF-1 is postulated to facilitate fibroblast proliferation, migration, and differentiation, augmenting the ability of fibroblasts to synthesize fibronectin and collagen, thereby boosting ECM deposition (Renaud et al., 2020).”
BackgroundTargeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Ma, H., Liu, S., Li, S., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918771 · Cited by 62 · cited 1×
“While both drugs mitigate the pace of IPF progression and lung function degradation, they fall short of reversing the lung damage inflicted by the disease (Ma et al., 2022).”
BackgroundLambers, C., Roth, M., Jaksch, P., Muraközy, G., Tamm, M., Klepetko, W., Ghanim, B., & Zhao, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19294-1 · Cited by 61 · cited 1×
“It also demonstrates dosedependent prevention of fibroblast proliferation to decrease extracellular matrix composition via TGF-beta1 in human peripheral lung fibroblasts (Lambers et al., 2018).”
BackgroundConnective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge
Effendi, W. I., & Nagano, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116064 · Cited by 60 · cited 1×
“CTGF, or CCN2, is recognized as a prolific instigator of chronic fibrosis hyperplasia (Sgalla et al., 2020a; Effendi and Nagano, 2022).”
BackgroundEffectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis
Tran, T., Assayag, D., Ernst, P., & Suissa, S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2080 · Cited by 60 · cited 1×
“PPIs are currently under investigation as potential therapeutic agents for IPF due to the frequent coexistence of gastroesophageal reflux disease and IPF in clinical scenarios (Tran et al., 2021).”
BackgroundHe, J., Li, X., & Yu, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.788417 · Cited by 60 · cited 1×
“The disease is predominantly observed in middle-aged to elderly men, and its global prevalence is estimated to exceed 3 million people, with an annual incidence rate between 2 and 9 per 100,000 individuals and an escalating trend (He et al., 2021a).”
BackgroundPamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59 · cited 2×
“CTGF, or CCN2, is recognized as a prolific instigator of chronic fibrosis hyperplasia (Sgalla et al., 2020a; Effendi and Nagano, 2022).”
BackgroundBae, W., Lee, C., Lee, J., Kim, Y. W., Han, K., & Choi, S. M. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215386 · Cited by 59 · cited 1×
“One study established that cigarette smoking correlates with an augmented risk of IPF, with ever-smokers facing a 60% elevated risk (Bae et al., 2022).”
BackgroundKhan, F. A., Stewart, I., Saini, G., Robinson, K. A., & Jenkins, R. G. (2022) · European Respiratory Journal · doi:10.1183/13993003.01612-2021 · Cited by 57 · cited 1×
“Clinical data suggest an association between elevated MMP-7 levels and an increased risk of mortality and disease progression (Khan et al., 2022).”
BackgroundNtolios, P., Manoloudi, E., Tzouvelekis, A., Bouros, E., Steiropoulos, P., Anevlavis, S., Bouros, D., & Froudarakis, M. E. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12777 · Cited by 56
Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis
Espíndola, M. S., Habiel, D. M., Coelho, A. L., Stripp, B. R., Parks, W. C., Oldham, J. M., Martínez, F. J., Noth, I., Lopez, D., Mikels, A. J., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1977oc · Cited by 56 · cited 1×
“IPF patients exhibit elevated MMP levels in alveolar lavage fluid and blood (Inoue et al., 2020; Espindola et al., 2021).”
Backgroundd’Alessandro, M., Bergantini, L., Cameli, P., Pieroni, M., Refini, R. M., Sestini, P., & Bargagli, E. (2021) · Cancers · doi:10.3390/cancers13040689 · Cited by 56
Teague, T., Payne, S. R., Kelly, B. T., Dempsey, T. M., McCoy, R. G., Sangaralingham, L. R., & LIMPER, A. H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02001-0 · Cited by 56 · cited 1×
“A retrospective clinical examination of IPF patients with concurrent diabetes revealed that the group treated with metformin exhibited lower all-cause mortality and hospitalization rates compared to the control group (Teague et al., 2022).”
BackgroundLee, C. M., Lee, D. H., Ahn, B. K., Hwang, J. J., Yoon, H., Shin, C. M., Park, Y. S., & Kim, N. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15192 · Cited by 55 · cited 1×
“Furthermore, a longer duration of PPI use was significantly associated with lower IPF-related mortality in both univariate and multivariate Cox regression analyses (Lee et al., 2016).”
BackgroundSun, W., Jing, X., Yang, X., Huang, H. F., Luo, Q., Xia, S., Wang, P., Wang, N., Zhang, Q., Guo, J., et al. (2021) · Aging · doi:10.18632/aging.203335 · Cited by 55 · cited 1×
“Mice with bleomycin-induced lung fibrosis and human IPF lung tissue have exhibited elevated IGF-1 levels (Sun et al., 2021).”
BackgroundSarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?
Collins, B. F., McClelland, R. L., Ho, L. A., Mikacenic, C. R., Hayes, J., Spada, C. A., & Raghu, G. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.08.008 · Cited by 54
Dinh, P.-U. C., Cores, J., Hensley, M. T., Vandergriff, A. C., Tang, J., Allen, T. A., Caranasos, T. G., Adler, K. B., Lobo, L. J., & Cheng, K. (2017) · Respiratory Research · doi:10.1186/s12931-017-0611-0 · Cited by 50 · cited 1×
“When administered intravenously into a mouse model of pulmonary fibrosis, a majority of the cells localized in the animal’s lungs, with the lung spheroid cells demonstrating potent regenerative properties (Dinh et al., 2017).”
BackgroundInsulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions
Garrett, S. M., Hsu, E., Thomas, J. M., Pilewski, J. M., & Feghali‐Bostwick, C. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225422 · Cited by 49 · cited 1×
“Studies indicate that IGF promotes the pro-fibrotic milieu chiefly through IGF1R signaling pathways, by suppressing matrix metalloproteinases, up-regulating TGFβ, and secreting tissue metalloproteinase inhibitors (Garrett et al., 2019).”
BackgroundInhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis
Kasam, R. K., Ghandikota, S. K., Soundararajan, D., Reddy, G. B., Huang, S. K., Jegga, A. G., & Madala, S. K. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012131 · Cited by 49 · cited 1×
“In IPF patients, CTGF expression is elevated in alveolar cells and mesenchymal fibroblasts (Kasam et al., 2020).”
BackgroundBiondini, D., Cocconcelli, E., Bernardinello, N., Lorenzoni, G., Rigobello, C., Lococo, S., Castelli, G., Baraldo, S., Cosio, M. G., Gregori, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01694-z · Cited by 48 · cited 1×
“, 2021), predominantly associated with pulmonary fibrosis (Biondini et al., 2021).”
BackgroundDi Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46
Mitochondrial Quality Control in Age-Related Pulmonary Fibrosis
Roque, W., Cuevas-Mora, K., & Romero, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020643 · Cited by 46 · cited 1×
“The exact origins and progression mechanisms of IPF remain ambiguous, with aging recognized as the most considerable risk factor (Roque et al., 2020a).”
BackgroundThe Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Behr, J. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0875 · Cited by 44 · cited 1×
“Historically, chronic inflammation, seemingly uncontrollable, was perceived as the primary driver of progressive parenchymal fibrosis development (Behr, 2013).”
BackgroundZhang, C., Yin, X., Zhang, J., Ao, Q., Gu, Y., & Liu, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4222 · Cited by 43 · cited 1×
“Nomajor adverse events were reported, thereby alleviating the majority of concerns (Glassberg et al., 2017; Zhang et al., 2017; Campo et al., 2021).”
BackgroundMostafaei, S., Sayad, B., Azar, M. E. F., Doroudian, M., Hadifar, S., Behrouzi, A., Riahi, P., Hussen, B. M., Bayat, B., Nahand, J. S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01650-x · Cited by 42 · cited 1×
“Additional contributing factors include genetics, environmental exposure, smoking habits, viral infections, gastroesophageal reflux disease, and fibrogenesis, all playing roles in IPF manifestation (Mostafaei et al., 2021).”
BackgroundDrankowska, J., Kos, M., Kościuk, A., Marzęda, P., Boguszewska‐Czubara, A., Tylus, M., & Święch-Zubilewicz, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.038 · Cited by 41 · cited 1×
“Encouraging abnormal epithelial cell migration and other irregular repair processes (Drankowska et al., 2019).”
BackgroundExtracellular Vesicles from Airway Secretions: New Insights in Lung Diseases
Pastor, L., Vera, E., Marín, J. M., & Sánz-Rubio, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020583 · Cited by 41 · cited 1×
“Studies indicate an upregulation of miR-21 in exosomes in mouse pulmonary fibrosis models and human IPF patient serum, correlating with disease progression and mortality (Pastor et al., 2021).”
BackgroundMetformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.
Xiao, H., Huang, X., Wang, S., Liu, Z., Dong, R., Song, D., & Dai, H. (2020) · PubMed · Cited by 40
Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis
Kletukhina, S. K., Mutallapova, G., Андреевна, Т. А., & Gomzikova, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911212 · Cited by 40 · cited 1×
“Stem cells, essentially immature cells that proliferate and metamorphose into adult cells, demonstrate anti-inflammatory and anti-fibrotic traits, rendering them as a potent potential therapy for fibrotic diseases (Kletukhina et al., 2022).”
BackgroundIdiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Balestro, E., Cocconcelli, E., Tinè, M., Biondini, D., Faccioli, E., Saetta, M. P., & Rea, F. (2019) · Medicina · doi:10.3390/medicina55100702 · Cited by 38 · cited 1×
“Lung transplantation presents itself as the sole treatment alternative that can enhance the quality of life and augment survival rates when previous treatments have failed to yield positive outcomes (Balestro et al., 2019).”
BackgroundMetformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice
Choi, S. M., Jang, A.-H., Kim, H., Lee, K. H., & Kim, Y. W. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.9.1419 · Cited by 36 · cited 2×
“2 Metformin Metformin, a time-honored hypoglycemic agent clinically employed in the treatment of type 2 diabetes mellitus, is increasingly recognized for its antifibrotic properties, as corroborated by numerous preclinical investigations (Choi et al., 2016; Rangarajan et al., 2018; Foretz et al., 2019).”
Background1143: METFORMIN AMELIORATES BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE BY SUPPRESSING IGF-1
Xiao, H., Huang, X., Wang, S., Liu, Z., Dong, R., Song, D., Zhang, X., & Dai, H. (2019) · Critical Care Medicine · doi:10.1097/01.ccm.0000643508.83802.5f · Cited by 36
Selman, M., Martinez, F. J., & Pardo, A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 35 · cited 1×
“Research indicates that cellular senescence induced by telomere degradation primarily afflicts alveolar epithelial type II cells, which is intricately linked to IPF pathogenesis (Stuart et al., 2014; Selman et al., 2019).”
Backgroundd’Alessandro, M., Soccio, P., Bergantini, L., Cameli, P., Scioscia, G., Barbaro, M. P. F., Lacedonia, D., & Bargagli, E. (2021) · Cells · doi:10.3390/cells10051045 · Cited by 35
Yang, S., Liu, P., Gao, T., Song, D., Zhao, X., Li, Y., Wu, J., Wang, L., Wang, Z., Hao, J., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02839-7 · Cited by 34
Eltahir, H. M., & Nazmy, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.028 · Cited by 33 · cited 1×
“Anti-fibrotic impacts of PPIs were evident in lung injury models induced by carbon tetrachloride, a liver fibrosis model (Eltahir and Nazmy, 2018).”
BackgroundCampo, A., González‐Ruiz, J. M., Andreu, E. J., Alcaide, A. B., Ocón, M. D. M., de-Torres, J. P., Pueyo, J. C., Cordovilla, R., Villarón, E. M., Sanchez-Guijo, F. M., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00773-2020 · Cited by 31 · cited 1×
“Nomajor adverse events were reported, thereby alleviating the majority of concerns (Glassberg et al., 2017; Zhang et al., 2017; Campo et al., 2021).”
BackgroundHan, M., Song, Y., Liu, S., Lu, X., Su, L., Liu, M., Zhu, X., Sun, K., Lu, Y., & Wang, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.882678 · Cited by 28
Fishman, J. E., Kim, G. H. J., Kyeong, N. Y., Goldin, J. G., & Glassberg, M. (2019) · PubMed · doi:10.26355/eurrev_201909_18877 · Cited by 27 · cited 1×
“In terms of efficacy, patients receiving the treatment displayed significant improvement in FVC compared to the placebo group (Ntolios et al., 2018; Fishman et al., 2019; Averyanov et al., 2020), with these results being considerably encouraging.”
ResultExosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis
Yang, Y., Liu, Y., Chai, Y., Liu, K., Hu, W., Zhao, K., Zhu, Y., Gao, P., Huang, Q., & Zhang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927653 · Cited by 27
Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model
Nelson, C., Lee, J., Ko, K., Sikora, A. G., Bonnen, M., Enkhbaatar, P., & Ghebre, Y. T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00016 · Cited by 26
Myeloid Fbxw7 Prevents Pulmonary Fibrosis by Suppressing TGF-β Production
He, J., Du, Y. J., Li, G., Xiao, P., Sun, X., Song, W., Lai, L., Meng, X., Zhang, J., & Wang, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760138 · Cited by 26
Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation
Veit, T., Leuschner, G., Sisic, A., Ceelen, F., Munker, D., Schmitzer, M., Weig, T. G., Michel, S. G., Schneider, C. P., Meiser, B., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15378 · Cited by 25 · cited 1×
“In IPF treatment, pirfenidone demonstrates not only tolerability but also a desirable safety profile (Veit et al., 2019).”
BackgroundRoque, W., Boni, A. J., Manzano, J. M. M., & Romero, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113878 · Cited by 25 · cited 1×
“This family of endopeptidases, including MMP-3, MMP-7, and MMP-8, is integral to regulating EMT degradation in IPF (Roque et al., 2020b; Bormann et al., 2022).”
BackgroundNelkine, L., Vrolijk, M. F., Drent, M., & Bast, A. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000684 · Cited by 23 · cited 1×
“Several cell biology experiments and preclinical studies indicate that gastric reflux constituents, such as acid and proteases, can elicit adverse effects such as immune response stimulation, enhanced cell membrane permeability, severe airway inflammation, and lung tissue structure alteration (Nelkine et al., 2020).”
BackgroundOccupational exposures and idiopathic pulmonary fibrosis
Walters, G. I. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000610 · Cited by 22 · cited 1×
“A noteworthy surge in IPF incidence is observable among individuals with exposure to animal dust, chemical fumes, metal dust (including lead and steel), and other pollutants (Walters, 2020).”
BackgroundAntibody-based therapies for idiopathic pulmonary fibrosis
Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 22 · cited 1×
“Pamrevlumab is presently under investigation in a Phase 3 randomized, double-blind, controlled, multicenter trial (Sgalla et al., 2020b).”
BackgroundLambert, E. M., Wuyts, W. A., Yserbyt, J., & Sadeleer, L. D. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106259 · Cited by 22 · cited 1×
“The mean survival time post-diagnosis is a mere 3–5 years (Lambert et al., 2021), and clinically, IPF is associated with dyspnea, a relentless decline in lung function, a dismal prognosis, and disease trajectories that span from gradual deterioration to swift collapse, culminating in mortality due to respiratory failu…”
BackgroundKim, S. W., Lim, J. Y., Rhee, C. K., Kim, J. H., Park, C. K., Kim, T. J., Cho, C. S., Min, C., & Yoon, H. K. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.02.002 · Cited by 22 · cited 1×
“Several experiments have established the inhibition of pulmonary fibrosis by PDE4 inhibitors (Kim et al., 2016; Herrmann et al., 2022).”
BackgroundExosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis
Negrete-García, M. C., Ramos-Abundis, J. D. J., Alvarado‐Vásquez, N., Montes-Martínez, E., Montaño, M., Ramos, C., & Sommer, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911047 · Cited by 22 · cited 1×
“Exosomes are phospholipid bilayer membranous vesicles, measuring between 30 and 150 nm (Negrete-Garcia et al., 2022).”
BackgroundTran, T., & Suissa, S. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa242 · Cited by 21 · cited 1×
“Given the influence of GERD on IPF progression, proton pump inhibitors are recommended for the management of this disease and have been incorporated into international IPF treatment guidelines (Tran and Suissa, 2021).”
BackgroundAcute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
Yamazoe, M., & Tomioka, H. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000342 · Cited by 21 · cited 1×
“Some studies have shown that the combination of them is beneficial in prolonging the survival of acute patients (Yamazoe and Tomioka, 2018).”
BackgroundSgalla, G., Simonetti, J., Cortese, S., & Richeldi, L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2173061 · Cited by 19 · cited 1×
“BI 1015550, a preferential Phosphodiesterase 4 (PDE4) inhibitor, has been developed for the treatment of IPF and other forms of progressive pulmonary fibrosis (Sgalla et al., 2023).”
BackgroundRasaei, R., Tyagi, A., Rasaei, S., Lee, S., Yang, S., Kim, K.-S., Ramakrishna, S., & Hong, S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03136-z · Cited by 18 · cited 1×
“By delivering miRNA to recipient cells, exosomes regulate diverse inflammatory and angiogenic pathways, playing an instrumental role in inflammation, tissue repair, and fibrogenesis (Rasaei et al., 2022).”
BackgroundBlumer, S., Fang, L., Chen, W., Khan, P., Hostettler, K., Tamm, M., Roth, M., & Lambers, C. (2021) · Cells · doi:10.3390/cells10112836 · Cited by 17
Effect of transplanted adipose-derived stem cells in mice exhibiting idiopathic pulmonary fibrosis
Jiang, H., Zhang, J., Zhang, Z., Ren, S., & Zhang, C. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4178 · Cited by 14 · cited 1×
“The potential engagement of MSCs in pulmonary fibrosis hinges on their capacity to generate a plethora of biologically active substances with anti-inflammatory, immunosuppressive, and angiogenic attributes, alongside their ability to minimize extracellular matrix and collagen deposition, thus fostering alveolar repair…”
BackgroundKim, S. W., Lim, J. Y., Rhee, C. K., Kim, J. H., Park, C. K., Kim, T. J., Cho, C. S., Min, C., & Yoon, H. K. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.011 · Cited by 12
Chen, S., Chen, H., Cheng, Y., Yu, W., Zhou, X., Tian, L., Zhu, J., & Wang, Q. (2019) · Medical Science Monitor · doi:10.12659/msm.915628 · Cited by 12 · cited 1×
“Evidence supporting this hypothesis emerges from descriptive studies conducted in both experimental animal models and humans (Chen et al., 2019; Reynolds et al., 2023).”
Kheirollahi, V., Khadim, A., Kiliaris, G., Korfei, M., Barroso, M. M., Alexopoulos, I., Vazquez‐Armendariz, A. I., Wygrecka, M., Ruppert, C., Günther, A., et al. (2022) · Cells · doi:10.3390/cells11121973 · Cited by 12 · cited 1×
“The insulin-like growth factor has a significant role in pulmonary fibrosis progression (Kheirollahi et al., 2022).”
BackgroundJiang, S., Xu, Z., Shi, Y., Liang, S., Jiang, X., Xiao, M., Wang, K., & Ding, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1126397 · Cited by 12
Futuro del tratamiento farmacológico en fibrosis pulmonar idiopática
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.05.008 · Cited by 10
The future of pharmacological treatment in idiopathic pulmonary fibrosis
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.05.012 · Cited by 10
Tanaka, K., Shimoda, M., Sugizaki, T., Ikeda, M., Takafuji, A., Kawahara, M., Yamakawa, N., & Mizushima, T. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00851-7 · Cited by 8 · cited 1×
“Both drugs function to curb fibroblast proliferation, obstruct collagen production, and diminish fibrogenic mediator production (Tanaka et al., 2022).”
BackgroundZhang, A., Zou, Y., Xu, Q., Tian, S., Wang, J., Li, Y., Dong, R., Zhang, L., Jiang, J., Wang, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919388 · Cited by 7 · cited 1×
“, 2021), and clinically, IPF is associated with dyspnea, a relentless decline in lung function, a dismal prognosis, and disease trajectories that span from gradual deterioration to swift collapse, culminating in mortality due to respiratory failure (Zhang et al., 2022).”
Background
Cited by
Pulmonary fibrosis: pathogenesis and therapeutic strategies
Wang, J., Li, K., Hao, D., Li, X., Zhu, Y., Yu, H., & Chen, H. (2024) · MedComm · doi:10.1002/mco2.744 · Cited by 149
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80
Mohanan, A., Washimkar, K. R., & Mugale, M. N. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119676 · Cited by 38
Nets in fibrosis: Bridging innate immunity and tissue remodeling
Ma, X., Ji-pin, L., Li, M., Qi, G., Wei, L., & Zhang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112516 · Cited by 33
Harrell, C. R., Djonov, V., Volarevic, A., Arsenijević, A., & Volarević, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084378 · Cited by 30
“Despite immunosuppressant medications, the body’s immune sys-tem may still recognize the transplanted lung as foreign and mount an allogeneic immune response, leading to organ rejection [14,15].”
Background
Metadata
- Authors
- Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y.
- Affiliations
- Huazhong University of Science and Technology (CN)
- Corresponding author
- Zeng, Yulan
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-08-07
- Volume
- 14
- Pages
- 1205948-1205948
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10440605
- OpenAlex
- W4385637349
- Cited by
- 41
- References
- 168
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 16 · 2023: 1
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, interstitial lung disease, myofibroblast differentiation, alveolar epithelial cell injury, extracellular matrix accumulation, collagen deposition, antifibrotic therapy, pirfenidone, nintedanib, lung transplantation, new drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.